These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20172522)

  • 1. Translational research in women's health: from bedside to bench and from bench to bedside.
    Maruo T
    Int J Gynaecol Obstet; 2010 May; 109(2):83-4. PubMed ID: 20172522
    [No Abstract]   [Full Text] [Related]  

  • 2. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system.
    Maruo T; Ohara N; Yoshida S; Nakabayashi K; Sasaki H; Xu Q; Chen W; Yamada H
    Contraception; 2010 Nov; 82(5):435-41. PubMed ID: 20933117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine fibroids and evidence-based medicine--not an oxymoron.
    Stewart EA
    N Engl J Med; 2012 Feb; 366(5):471-3. PubMed ID: 22296082
    [No Abstract]   [Full Text] [Related]  

  • 4. Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumes.
    Murat Naki M; Tekcan C; Ozcan N; Cebi M
    Fertil Steril; 2010 Jun; 94(1):371-4. PubMed ID: 19896649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestin-releasing intrauterine systems and leiomyoma.
    Kaunitz AM
    Contraception; 2007 Jun; 75(6 Suppl):S130-3. PubMed ID: 17531604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future medical treatments for menometrorrhagia during the premenopause.
    Bouchard P
    Gynecol Endocrinol; 2011 Dec; 27 Suppl 1():1120-5. PubMed ID: 22182055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas.
    Maruo T; Ohara N; Matsuo H; Xu Q; Chen W; Sitruk-Ware R; Johansson ED
    Contraception; 2007 Jun; 75(6 Suppl):S99-103. PubMed ID: 17531625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?
    Donnez J; Donnez O; Dolmans MM
    Fertil Steril; 2014 Sep; 102(3):640-8. PubMed ID: 25106762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of selective progesterone receptor modulators in the treatment of myomas].
    Šimetka O; Klát J
    Ceska Gynekol; 2016; 81(4):317-320. PubMed ID: 27882756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The possibility of using progesterone receptor modulators in the treatment of myomas].
    Šimetka O; Klát J; Bajsová S
    Ceska Gynekol; 2016; 81(6):452-457. PubMed ID: 27918164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
    Singh SS; Belland L; Leyland N; von Riedemann S; Murji A
    Am J Obstet Gynecol; 2018 Jun; 218(6):563-572.e1. PubMed ID: 29274830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
    Magalhães J; Aldrighi JM; de Lima GR
    Contraception; 2007 Mar; 75(3):193-8. PubMed ID: 17303488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study.
    Gunes M; Ozdegirmenci O; Kayikcioglu F; Haberal A; Kaplan M
    J Minim Invasive Gynecol; 2008; 15(6):735-8. PubMed ID: 18971138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
    Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
    Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esmya
    Powell M; Dutta D
    Womens Health (Lond); 2016 Nov; 12(6):544-548. PubMed ID: 29334010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ulipristal acetate and SPRM: A new entity for the therapeutic strategy for symptomatic myomas].
    Fernandez H
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):671-672. PubMed ID: 30293948
    [No Abstract]   [Full Text] [Related]  

  • 19. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective progesterone receptor modulators.
    Whitaker LH; Williams AR; Critchley HO
    Curr Opin Obstet Gynecol; 2014 Aug; 26(4):237-42. PubMed ID: 24950125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.